Amicus Therapeutics Reaches Analyst Target Price
November 05, 2020 at 09:20 AM EST
In recent trading, shares of Amicus Therapeutics Inc (FOLD) have crossed above the average analyst 12-month target price of $20.06, changing hands for $20.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..